NEW YORK (GenomeWeb) – Acarix recently began placing its CADScor system with European laboratories, marketing the acoustic diagnostic as a noninvasive first-line test for ruling out coronary artery disease for patients presenting with chest pains.

Since it launched CADscor in the second quarter, Acarix has announced clients in Germany, Denmark, and Sweden. Earlier this month, the cardiology department at Skåne University Hospital in Lund decided to introduce the test, which has been cleared for clinical use in Europe since 2015.

Get the full story with
360Dx Premium

Only $95 for the
first 90 days*

360Dx Premium gives you:
✔ Full site access
✔ Interest-based email alerts
✔ Access to archives

Never miss another important industry story.

Try 360Dx Premium now.

You may already have institutional access!

Check if I qualify.

Already a 360Dx or GenomeWeb Premium member?
Login Now.

*Before your trial expires, we’ll put together a custom quote with your long-term premium options.

Not ready for premium?

Register for Free Content
You can still register for access to our free content.